Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche H1 "solid"

This article was originally published in Clinica

Executive Summary

Roche posted an overall “solid” set of first-half results, “with in-line revenues and core EPS 2% ahead of consensus”, according to Jefferies analyst Jeffrey Holford. Furthermore, diagnostics sales of CHF5.1bn ($5.4bn) were up 2% year-on-year (+3% at constant currency rates), 1% ahead of analyst expectations, Mr Holdford noted. This is a turnaround from Roche’s first quarter, when diagnostics were the weak link, with sales growing just 1% (www.clinica.co.uk, 11 April 2013). However, Roche’s pharma division was still the top performer in H1, with revenues climbing 4% to CHF18.2bn. Group H1 sales were CHF23.2bn, up 4% year-on-year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel